Avidity Biosciences (id:6466 RNA)
43.25 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 5:41:55 PM)
Exchange closed, opens in 1 day 15 hours
About Avidity Biosciences
Market Capitalization 5.58B
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Headquarters (address) |
10578 Science Center Drive San Diego 92121 CA United States |
| Phone | 858 401 7900 |
| Website | https://www.aviditybiosciences.com |
| Employees | 253 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | RNA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 5.97 - 56.00 |
| Market Capitalization | 5.58B |
| P/E trailing | -14.86 |
| P/E forward | -15.42 |
| Price/Sale | 551.08 |
| Price/Book | 3.70 |
| Beta | 0.908 |
| EPS | -2.95 |
| EPS United States (ID:6, base:3402) | 24.25 |